Trials / Terminated
TerminatedNCT03122548
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Aduro Biotech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior chemotherapy regimens for advanced disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CRS-207 | Administered by IV infusion over 1 hour. |
| BIOLOGICAL | Pembrolizumab | Administered by IV infusion over 30 minutes. |
Timeline
- Start date
- 2017-08-14
- Primary completion
- 2017-12-27
- Completion
- 2018-01-31
- First posted
- 2017-04-21
- Last updated
- 2019-04-04
- Results posted
- 2019-02-20
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03122548. Inclusion in this directory is not an endorsement.